Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 322, pseudogene (RNU6-322P), is a member of a large family of U6 small nuclear RNA (snRNA) pseudogenes found throughout vertebrate genomes[3][2]. Pseudogenes like RNU6-322P are non-functional, typically generated by retrotransposition events involving the active parental U6 snRNA gene, and do not produce functional RNA or protein products[3]. Functional U6 snRNA molecules are essential components of the spliceosomal complex, driving the removal of introns from pre-mRNA and playing a central structural and catalytic role in the spliceosome[1][2]. However, pseudogenes such as RNU6-322P lack this function; they serve primarily as genomic markers for retrotransposition activity and have no established direct biological or disease relevance[3][2]. They are not considered therapeutic targets, nor are they involved in known drug interactions or clinical biomarker strategies. Their presence is primarily of interest in evolutionary, genomic, or retrotransposon biology studies rather than molecular pharmacology or therapeutics[3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 322, pseudogene (RNU6-322P).